Ardsley Advisory Partners’s Mirum Pharmaceuticals MIRM Stock Holding History

Ardsley Advisory Partners’s Portfolio MIRM Stock Details MIRM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-190,000	Closed	-$7.86M	–	176
2024 Q4	$7.86M	Hold	190,000	–	–	1.25%	23
2024 Q3	$7.41M	Buy	190,000 +10,000	+6%	+$399K	1.22%	29
2024 Q2	$6.15M	Sell	180,000 -65,000	-27%	-$1.7M	0.9%	31
2024 Q1	$6.15M	Buy	245,000 +20,000	+9%	+$550K	0.88%	37
2023 Q4	$6.64M	Buy	225,000 +125,000	+125%	+$3.78M	1.03%	27
2023 Q3	$3.16M	Buy	+100,000	New	+$2.74M	0.71%	47

Other funds holding MIRM

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ardsley Advisory Partners's MIRM Position: Q1 2025 in Review

Ardsley Advisory Partners sold out of Mirum Pharmaceuticals (MIRM) in Q1 2025, closing a stake of 190,000 shares — an estimated $7.86M sold.

Ardsley Advisory Partners first reported a position in MIRM in Q3 2023 and held it in 6 quarters. The position peaked at $7.86M in Q4 2024. 214 funds tracked by Wall St. Rank hold MIRM as of Q1 2025.

Ardsley Advisory Partners reported no remaining Mirum Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Ardsley Advisory Partners sold 190,000 Mirum Pharmaceuticals shares in Q1 2025, an estimated $7.86M.
Ardsley Advisory Partners first reported a position in Mirum Pharmaceuticals in Q3 2023 and held it in 6 quarters.
Ardsley Advisory Partners's Mirum Pharmaceuticals position peaked at $7.86M in Q4 2024.
214 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q1 2025.

Based on Ardsley Advisory Partners's 13F filing for Q1 2025, filed 15 May 2025.